Interview: Patrice Carayon – CEO, Chiesi France
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
Chiesi is an international company based in Parma, with 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas.With a turnover of more than €1.3 billion sales, Chiesi is among the top 50 pharmaceutical companies in the world. They have production sites are in Parma, Italy, Blois (France) and Santana De Parnaiba (Brazil) and R&D centres in Parma (Italy), Paris (France), Rockville (USA), Chippenham (UK).
Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to accompany its commercial activities. In 2013 Chiesi announced an investment of 22 million euros (USD 23.90 million) in their production site in Blois. Significant investments in manufacturing capacity have been made. Previously, the site employed 60 people, by the end of 2016 this number will have almost doubled.
Chiesi was established in France in 1992 through its subsidiary ProMedica. In 1999, the Italian group strengthened its presence with the acquisition of Logeais Group. Today, the French subsidiary is directed by Patrice Carayon. It represents 8 percent of total Group sales with a turnover of 104 million euros in 2014. Subsidiary of primary importance, France is Chiesi´s fifth most important market.
Contact
Address: Immeuble le Doublon – 11 Avenue Dubonnet, 92400 Courbevoie – France
Tel: 33 1 47688899
Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to…
The basis of the pharmaceutical business model is changing. Take sales forces for instance, what will be the composition and daily routine? How much mixed media will it require? Currently,…
Biocodex has evolved from a pioneering French laboratory built around a single yeast strain into an international healthcare group spanning microbiota, women’s health and a focused orphan-disease activity. In this…
Nicolas Dufourt leads ALK France as General Manager, drawing on nearly two decades of tenure with the Danish allergy immunotherapy specialist. Under his stewardship, the French affiliate, comprising approximately 400…
France is reshaping its approach to obesity at a moment when scientific understanding, clinical practice and public expectations are all shifting. Dr Rudy Caillet offers a clear view of how…
With France at the forefront of rare disease expertise yet increasingly challenged on patient access, Amicus Therapeutics finds itself at the heart of both progress and paradox. In this interview,…
France has long been held up as Europe’s reference point for rare disease care – the first EU country with a national plan, a pioneer of coordinated expert networks, and…
With over two decades of international experience in the pharmaceutical industry, Olivier Zambelli brings both strategic vision and a deeply human approach to his role as President and General Manager…
With over 35 years of experience across major pharmaceutical markets, Corinne Blachier-Poisson, General Manager of Amgen France, she discusses Amgen France’s ambitions and the company’s pivotal role in shaping France’s…
After two decades with AstraZeneca across Europe and the United States, Anne-Laure Dreno now leads the group’s French affiliate at a time of exceptional scientific and organisational momentum. In this…
Launched in 2022 under the France 2030 biocluster programme, the Paris-Saclay Cancer Cluster (PSCC) is rapidly positioning itself as a new epicentre for oncology innovation in Europe. Under the leadership…
Founded in 1973, IFIS stands at the intersection of education, industry, and public policy, shaping the capabilities that underpin France’s global health leadership. Evolving from its origins as a training…
France is undergoing a quiet industrial renaissance in biomanufacturing, driven by a growing alignment between science, innovation, and policy. At the centre of this movement stands Laurent Lafferrère, CEO of…
With France now a cornerstone of its global strategy, Regeneron is accelerating its European expansion under the leadership of Antoine Catton. In less than two years, the affiliate has built…
See our Cookie Privacy Policy Here
